Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Profit After Tax (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Profit After Tax data on record, last reported at -$24.6 million in Q3 2025.

  • For Q3 2025, Profit After Tax fell 95.68% year-over-year to -$24.6 million; the TTM value through Sep 2025 reached -$82.0 million, down 140.35%, while the annual FY2024 figure was -$40.5 million, 81.57% down from the prior year.
  • Profit After Tax reached -$24.6 million in Q3 2025 per CAPR's latest filing, up from -$25.9 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$762089.0 in Q4 2023 and bottomed at -$25.9 million in Q2 2025.
  • Average Profit After Tax over 5 years is -$9.8 million, with a median of -$7.4 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: skyrocketed 90.13% in 2023, then plummeted 833.83% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$6.2 million in 2021, then decreased by 24.72% to -$7.7 million in 2022, then surged by 90.13% to -$762089.0 in 2023, then tumbled by 833.83% to -$7.1 million in 2024, then plummeted by 245.26% to -$24.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$24.6 million in Q3 2025, -$25.9 million in Q2 2025, and -$24.4 million in Q1 2025.